Genome-wide assays to characterize rAAV integration into human genomic DNA in vivo

Adeno-associated viral (AAV) vectors are used to treat genetic diseases, expressing therapeutic genes from both extrachromosomal episomes and payloads that integrate into the host genome. Assays were developed to evaluate HR-mediated on-target integration and the potential occurrence of off-target integration. While many studies have addressed elements of these processes, proper characterization requires long-read sequencing to ensure that integrated viral DNA is examined and not the more prevalent episomes. We used Oxford Nanopore to characterize integrated DNA and scan the whole genome for off-target integrations. These assays were applied to cell-based and in vivo models to study vectors that correct phenylketonuria (PKU), caused by loss of phenylalanine hydroxylase (PAH). Administration of the human-specific vector in a humanized-liver mouse xenograft model resulted in stable, nuclease-free integration into PAH. Because detection of rare integration events in a much larger pool of episomal DNA is subject to artifacts, careful assay validation was required. A long-read, genome-wide assay capable of detecting on- and off-target vector integrations showed no evidence of off-target integration. Artifactual false positive events were below the limit of blank. These data support rAAV as an investigational therapeutic for genetic diseases and reinforce the need for characterization of integration assays to avoid artifacts.

[1]  M. Gosink,et al.  Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs , 2023, Molecular therapy. Methods & clinical development.

[2]  Johnf . Thompson,et al.  LNA blockers for improved amplification selectivity , 2023, Scientific Reports.

[3]  J. Mullins,et al.  Droplet-microfluidics-assisted sequencing of HIV proviruses and their integration sites in cells from people on antiretroviral therapy , 2022, Nature Biomedical Engineering.

[4]  J. Rasko,et al.  Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. , 2021, The New England journal of medicine.

[5]  L. Feuk,et al.  CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations , 2021, bioRxiv.

[6]  G. Aquino-Jarquin Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing. , 2021, Molecular genetics and metabolism.

[7]  Xiaozhong Peng,et al.  Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome , 2021, Protein & Cell.

[8]  Ira W. Deveson,et al.  No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing , 2021, Cell Reports.

[9]  A. Seymour,et al.  Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH , 2020, Molecular therapy. Methods & clinical development.

[10]  S. Hughes,et al.  An analytical pipeline for identifying and mapping the integration sites of HIV and other retroviruses , 2020, BMC Genomics.

[11]  G. Vahedi,et al.  Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels , 2020, Proceedings of the National Academy of Sciences.

[12]  I. Alexander,et al.  High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction , 2020, Human gene therapy.

[13]  Taylor L. Mighell,et al.  AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria , 2019, Molecular therapy. Methods & clinical development.

[14]  S. Luquet,et al.  Insights From Liver‐Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR‐Agonist Pharmacodynamics in Humans , 2019, Hepatology.

[15]  M. Robinson,et al.  Treatment of a metabolic liver disease by in vivo genome base editing in adult mice , 2018, Nature Medicine.

[16]  J. González,et al.  Characterization of Plasmodium vivax Proteins in Plasma-Derived Exosomes From Malaria-Infected Liver-Chimeric Humanized Mice , 2018, Front. Microbiol..

[17]  S. S. St Martin,et al.  Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  L. Zentilin,et al.  Promoterless gene targeting without nucleases rescues lethality of a Crigler‐Najjar syndrome mouse model , 2017, EMBO molecular medicine.

[19]  Kyle Bittinger,et al.  INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes , 2016, Molecular therapy. Methods & clinical development.

[20]  John D. McGregor,et al.  Community , 2016, physiopraxis.

[21]  J. Prieto,et al.  Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  R. Siliciano,et al.  HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay , 2016, Journal of Virology.

[23]  J. Darnell,et al.  Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. , 2015, Gastroenterology.

[24]  Yong Huang,et al.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.

[25]  R. Redon,et al.  NGS library preparation may generate artifactual integration sites of AAV vectors , 2014, Nature Medicine.

[26]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[27]  Stephan Wolf,et al.  A largely random AAV integration profile after LPLD gene therapy , 2013, Nature Medicine.

[28]  F. Bushman,et al.  Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. , 2013, Human gene therapy.

[29]  Stephan Wolf,et al.  Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing , 2010, Nature Protocols.

[30]  B. Levine,et al.  A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. , 2008, Virology.

[31]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[32]  Aarati R. Ranade,et al.  Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice , 2007, Nature Biotechnology.

[33]  H. Drew,et al.  Increased complexity of wild-type adeno-associated virus-chromosomal junctions as determined by analysis of unselected cellular genomes. , 2007, The Journal of general virology.

[34]  R. Calne,et al.  Gene therapy for hemophilia A. , 2006, Discovery medicine.

[35]  Daniel G. Miller,et al.  Adeno-associated virus vectors integrate at chromosome breakage sites , 2004, Nature Genetics.

[36]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[37]  H. C. Lee,et al.  Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma , 2004, British Journal of Cancer.

[38]  M. R. Delgado Alvira,et al.  Adeno-associated viruses undergo substantial evolution in primates during natural infections , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Prerna Sharma,et al.  Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue , 1998, Journal of Virology.

[40]  M. Kay,et al.  The kinetics of rAAV integration in the liver , 1998, Nature Genetics.

[41]  R. Kotin,et al.  Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination. , 1992, The EMBO journal.

[42]  D. Housman,et al.  Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.

[43]  S. Strom,et al.  Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. , 2010, Methods in molecular biology.

[44]  L. Work,et al.  Genetic Vaccines and Therapy , 2008 .

[45]  L. Work,et al.  Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats , 2008 .